Interact with experts and peers.

Recent Posts

10 of 86 Shown
  • My Thoughts on Immunotherapy and PD-L1 Testing in Metastatic Lung Adenocarcinoma

    Leora Horn MD, MSc, FRCPC - 7/8/2016 2 comments / Last Comment: 7/12/2016
    Are you considering immunotherapy for your patients with metastatic lung adenocarcinoma? Leora Horn, MD, MSc, FRCPC, shares her thoughts on the role of PD-L1 testing in selection of immune checkpoint inhibitors.
  • How I Manage Treatment-Related Toxicity in Refractory Metastatic Colorectal Cancer

    John L. Marshall MD - 7/1/2016 1 comment / Last Comment: 7/6/2016
    Treatment decisions in the refractory setting must consider the accumulated toxicities that patients have endured during previous rounds of therapy as well as the additional potential toxicities associated with the next treatment.
  • Targeting CD123 in AML

    Jonathan Webster MD - 6/28/2016 1 comment / Last Comment: 7/22/2016
    Targeting CD123 in AML with multiple approaches shows promise as a novel treatment for this challenging disease.
  • How I Choose Second-line Treatment After Crizotinib Failure in Advanced NSCLC

    Tony Mok MD - 6/20/2016 1 comment / Last Comment: 6/27/2016
    Despite improving outcomes for patients with ALK-positive NSCLC, many patients will relapse on initial therapy with crizotinib. In this commentary, I review second-generation ALK inhibitors that are becoming available as second-line therapy and provide considerations for matching specific agents to patients.
  • Biologic Therapies in Metastatic Colorectal Cancer: Mastering Your Moves Beyond First Line

    John L. Marshall MD - 6/10/2016 5 comments / Last Comment: 6/14/2016
    Selecting therapies for metastatic CRC through subsequent lines of therapy can often feel like a chess match. Here’s my approach.
  • Expert Perspective on the Top Hematologic Malignancy Studies From the 2016 Clinical Oncology Meeting

    Shaji Kumar MD - 5/31/2016 1 comment / Last Comment: 6/1/2016
    Here are expert thoughts on the hematologic malignancies abstracts from ASCO 2016 that have the most potential to change clinical practice.
  • Lung Cancer: Looking Ahead to the 2016 Clinical Oncology Meeting

    Heather Wakelee MD - 5/31/2016 4 comments / Last Comment: 6/16/2016
    Here are the studies being presented at ASCO 2016 that David R. Gandara, MD, and I think are most likely to affect clinical practice in our patients with lung cancer.
  • GU Malignancies at the 2016 Clinical Oncology Meeting: In Anticipation of Practice-Changing Data

    Brian Rini MD, FACP - 5/31/2016
    Here are my thoughts on the abstracts from ASCO 2016 that have the most potential to change clinical practice.
  • Breast Cancer: A Look Ahead to Practice-Changing Data at the 2016 Clinical Oncology Meeting

    Sara Hurvitz MD, FACP - 5/31/2016 6 comments / Last Comment: 6/12/2016
    Here are the breast cancer abstracts that I am most interested in hearing about at this year’s ASCO annual meeting.
  • Addressing Financial Challenges With Use of New Immunotherapies for Relapsed ALL

    Jonathan Webster MD - 5/19/2016 2 comments / Last Comment: 6/17/2016
    How do you manage the potential financial challenges to prescribing blinatumomab and other novel immunotherapies for your patients who may benefit from these therapies?
10 of 86 Shown
Show 10 More